Please login to the form below
Belsomra
This page shows the latest Belsomra news and features for those working in and with pharma, biotech and healthcare.
Merck gets Alzheimer’s label claim for insomnia drug Belsomra
Critically, unlike some other insomnia drugs like zolpidem, Belsomra doesn’t seem to lead to a significant increase in confusion and falls in people who are cognitively impaired. ... Peak sales of Belsomra are expected to reach around $500m, with the
Latest news
-
Relief as study finds no cardiovascular risk with Januvia
Meanwhile, first-in-class insomnia therapy Belsomra (suvorexant) and new antibiotic Zerbaxa (ceftolozane/tazobactam) also got off to a good start, according to chief executive Kenneth Frazier.
-
FDA approves Merck’s insomnia drug
Belsomra is first orexin receptor antagonist available in US. People with the sleep disorder insomnia now have access to a new treatment option after the FDA approved Merck &Co's Belsomra. ... To cover the varying severity of the disorder, Belsomra is
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
